“Neutral” rating 2seventy bio (TSVT) confirmed on Wedbush

Wedbush reaffirmed neutral rating on stock 2seventy bio (NASDAQ:TSVT – Free Report) in a report released Thursday, Benzinga reports. They currently have a $5.00 price target on the stock.

Several other equity analysts also recently commented on TSVT. Canaccord Genuity Group upgraded shares of 2seventy bio to a Strong Buy rating in a research report on Thursday, May 9th. Citigroup increased their target price on shares of 2seventy bio from $9.00 to $12.00 and gave the company a “buy” rating in a report on Monday, April 8. Canaccord Genuity Group lowered their target price on shares of 2seventy bio from $12.00 to $11.00 and set a “buy” rating for the company in a report on Thursday, May 9th. Finally, The Goldman Sachs Group lowered shares of 2seventy bio from a Neutral rating to a Sell rating and lowered their price target for the company from $5.00 to $2.00 in a report on Thursday, June 6th. One analyst has rated the stock as a sell, four have rated the stock with a hold rating, four have rated the stock with a buy rating and one has rated the company’s stock with a strong buy rating. According to MarketBeat.com, the company has an average rating of Moderate Buy and an average price target of $12.43.

Read our latest research report on 2seventy bio

Results of the 2seventy bio campaign

Shares of 2seventy bio opened at $3.76 on Thursday. 2seventy bio has a 1-year low of $1.53 and a 1-year high of $11.29. The company has a 50-day moving average of $4.33 and a 200-day moving average of $4.52.

2seventy bio (NASDAQ:TSVT – Get Free Report) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, which was $0.09 below the analyst consensus estimate of $0.72. 2seventy bio had a negative return on equity of 67.59% and a negative net margin of 313.51%. The company had revenue of $12.44 million for the quarter, compared to the consensus estimate of $11.93 million. Analysts predict that 2seventy bio will post -0.93 EPS for the current fiscal year.

Institutional investors rate 2seventy bio

Large investors have recently changed their positions in the company. Madison Avenue Partners LP increased its holdings in 2seventy bio by 17.4% in the fourth quarter. Madison Avenue Partners LP now owns 1,754,788 shares of the company’s stock worth $7,493,000 after purchasing an additional 260,663 shares in the last quarter. Deutsche Bank AG increased its holdings in 2seventy bio by 15.7% in the third quarter. Deutsche Bank AG now owns 26,134 shares of the company’s stock worth $102,000 after purchasing an additional 3,537 shares during the period. Goldman Sachs Group Inc. increased its holdings in 2seventy bio by 512.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 4,508,800 shares of the company’s stock valued at $19,253,000 after purchasing an additional 3,772,556 shares during the last quarter. Public Employees Retirement System of Ohio increased its holdings in 2seventy bio by 112.6% in the third quarter. Public Employees Retirement System of Ohio now owns 84,757 shares of the company’s stock valued at $332,000 after purchasing an additional 44,895 shares during the period. Finally, Graham Capital Management LP increased its position in 2seventy bio by 195.0% during the third quarter. Graham Capital Management LP now owns 75,891 shares of the company’s stock valued at $297,000 after purchasing an additional 50,166 shares during the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

About 270 bio

(Get your free report)

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of cancer treatments in the United States. The company’s products include Abecma, a chimeric T-cell antigen receptor product candidate for the treatment of multiple myeloma.

Featured Stories

Get daily news and ratings for 2seventy bio – Enter your email address below to receive a concise summary of the latest news and analyst ratings for 2seventy bio and related companies in MarketBeat.com’s FREE daily newsletter.